Lilly’s COVID-19 treatment receives emergency-use approval from FDA, stock jumps 3%

Eli Lilly & Co.'s COVID-19 antibody treatment was approved for emergency use by the Food and Drug Administration on Monday, and Lilly shares jumped more than 3% in after-hours trading.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.